With the end of the COVID-19 Public Health Emergency and national emergency on May 11, 2023, Medicaid state agencies have begun the process of redetermining which Medicaid participants may no longer be eligible and, consequently, dropped from Medicaid. Precision’s Jorge Font addresses the potential impact to commercial/employer plan enrollment shifts resulting from the unwinding of Medicaid continuous coverage protection.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
